PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23671445-0 2013 Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Valproic Acid 0-13 killer cell lectin like receptor K1 Homo sapiens 26-31 30972064-3 2019 In the present study, we show that treatment with the histone deacetylase inhibitor Valproic acid (VPA) significantly enhanced the expression and/or release of the NKG2D ligands MICA, MICB and ULBP-2, but not ULBP-1 in the pancreatic carcinoma cell line Panc89 and the prostate carcinoma cell line PC-3. Valproic Acid 84-97 killer cell lectin like receptor K1 Homo sapiens 164-169 30972064-3 2019 In the present study, we show that treatment with the histone deacetylase inhibitor Valproic acid (VPA) significantly enhanced the expression and/or release of the NKG2D ligands MICA, MICB and ULBP-2, but not ULBP-1 in the pancreatic carcinoma cell line Panc89 and the prostate carcinoma cell line PC-3. Valproic Acid 99-102 killer cell lectin like receptor K1 Homo sapiens 164-169 24885711-1 2014 BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is reported to exert anti-tumor effects by upregulating the expression of the natural killer group 2D (NKG2D) ligands on tumor cells; however, the mechanisms vary in different tumor types, and the effect and mechanism of action of VPA in pancreatic cancer cells are unknown. Valproic Acid 12-25 killer cell lectin like receptor K1 Homo sapiens 151-174 24885711-1 2014 BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is reported to exert anti-tumor effects by upregulating the expression of the natural killer group 2D (NKG2D) ligands on tumor cells; however, the mechanisms vary in different tumor types, and the effect and mechanism of action of VPA in pancreatic cancer cells are unknown. Valproic Acid 12-25 killer cell lectin like receptor K1 Homo sapiens 176-181 24885711-1 2014 BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is reported to exert anti-tumor effects by upregulating the expression of the natural killer group 2D (NKG2D) ligands on tumor cells; however, the mechanisms vary in different tumor types, and the effect and mechanism of action of VPA in pancreatic cancer cells are unknown. Valproic Acid 27-30 killer cell lectin like receptor K1 Homo sapiens 151-174 24885711-1 2014 BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is reported to exert anti-tumor effects by upregulating the expression of the natural killer group 2D (NKG2D) ligands on tumor cells; however, the mechanisms vary in different tumor types, and the effect and mechanism of action of VPA in pancreatic cancer cells are unknown. Valproic Acid 27-30 killer cell lectin like receptor K1 Homo sapiens 176-181 35078573-1 2022 Objective To investigate the effect of sodium valproate (VPA) on the expression of NKG2D ligand and the killing effect of NK cells on melanoma cells through MEK/ERK signaling pathway. Valproic Acid 39-55 killer cell lectin like receptor K1 Homo sapiens 83-88 35078573-1 2022 Objective To investigate the effect of sodium valproate (VPA) on the expression of NKG2D ligand and the killing effect of NK cells on melanoma cells through MEK/ERK signaling pathway. Valproic Acid 57-60 killer cell lectin like receptor K1 Homo sapiens 83-88 23671445-1 2013 INTRODUCTION: We aimed to investigate the effect of valproic acid (VPA) on NKG2D ligand expression in human renal carcinoma cell lines and to investigate the mechanisms. Valproic Acid 52-65 killer cell lectin like receptor K1 Homo sapiens 75-80 23671445-1 2013 INTRODUCTION: We aimed to investigate the effect of valproic acid (VPA) on NKG2D ligand expression in human renal carcinoma cell lines and to investigate the mechanisms. Valproic Acid 67-70 killer cell lectin like receptor K1 Homo sapiens 75-80 23671445-4 2013 Real-time PCR and FCM were used to detect the changes of mRNA and protein level of NKG2D ligands (MICA/B and ULBPs) in the two cell lines treated with 4 mM VPA. Valproic Acid 156-159 killer cell lectin like receptor K1 Homo sapiens 83-88 23671445-7 2013 786-O and ACHN cells treated with VPA were more susceptible to killing by NK cells than untreated cells and the enhanced cytotoxicity of NK cells was blocked by the pretreatment of NK cells with anti-NKG2D monoclonal antibodies (p < 0.05). Valproic Acid 34-37 killer cell lectin like receptor K1 Homo sapiens 200-205 23671445-8 2013 CONCLUSIONS: Valproic acid can clearly induce the expression of NKG2D ligands of renal carcinoma cell lines, thereby enhancing the cytotoxicity of NK cells against renal carcinoma cell lines. Valproic Acid 13-26 killer cell lectin like receptor K1 Homo sapiens 64-69 21805029-0 2011 Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Valproic Acid 95-104 killer cell lectin like receptor K1 Homo sapiens 16-21 23297870-8 2013 Notably, pretreatment of ovarian cancer cells expressing moderate to low levels of NKG2DLs with the histone deacetylase inhibitor sodium valproate (VPA) upregulated NKG2DL cell surface expression and consequently enhanced their immune recognition by chimeric NKG2D CAR T cells. Valproic Acid 130-146 killer cell lectin like receptor K1 Homo sapiens 83-88 23297870-8 2013 Notably, pretreatment of ovarian cancer cells expressing moderate to low levels of NKG2DLs with the histone deacetylase inhibitor sodium valproate (VPA) upregulated NKG2DL cell surface expression and consequently enhanced their immune recognition by chimeric NKG2D CAR T cells. Valproic Acid 148-151 killer cell lectin like receptor K1 Homo sapiens 83-88 23297870-9 2013 Our results demonstrate that VPA-induced upregulation of NKG2DL expression enhances the immune recognition of ovarian cancer cells by engineered NKG2D CAR T cells, and rationalizes the use of VPA in combination with NKG2DL-targeted immunotherapy in ovarian cancer. Valproic Acid 29-32 killer cell lectin like receptor K1 Homo sapiens 57-62 23308050-0 2012 Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Valproic Acid 0-13 killer cell lectin like receptor K1 Homo sapiens 26-31 23308050-2 2012 In this study, we tested the effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on the expression of NKG2D ligands in myeloma cells. Valproic Acid 39-52 killer cell lectin like receptor K1 Homo sapiens 121-126 23308050-2 2012 In this study, we tested the effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on the expression of NKG2D ligands in myeloma cells. Valproic Acid 54-57 killer cell lectin like receptor K1 Homo sapiens 121-126 23308050-8 2012 These data indicate that increased sensitivity of VPA-treated myeloma cells to NK cell lysis is caused by higher NKG2D ligand expression, resulting from more active ERK signaling pathway. Valproic Acid 50-53 killer cell lectin like receptor K1 Homo sapiens 113-118 22167753-3 2012 NKG2D-L-negative RS cells could not be killed by CD8(+)alphabetaT or gammadeltaT cells; tumor cell killing was partially restored by treating RS cells with valproic acid, which enhanced NKG2D-L surface expression. Valproic Acid 156-169 killer cell lectin like receptor K1 Homo sapiens 0-5 22167753-3 2012 NKG2D-L-negative RS cells could not be killed by CD8(+)alphabetaT or gammadeltaT cells; tumor cell killing was partially restored by treating RS cells with valproic acid, which enhanced NKG2D-L surface expression. Valproic Acid 156-169 killer cell lectin like receptor K1 Homo sapiens 0-7 19608675-6 2009 The HDAC inhibitor valproic acid increased the activating NKG2D ligand-dependent lysis of acute myeloid leukemia-CD34(+)CD38(-) leukemic stem cells. Valproic Acid 19-32 killer cell lectin like receptor K1 Homo sapiens 58-63 21042760-0 2010 Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Valproic Acid 0-16 killer cell lectin like receptor K1 Homo sapiens 91-96 21115900-0 2010 The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands. Valproic Acid 63-76 killer cell lectin like receptor K1 Homo sapiens 102-107 21115900-7 2010 CONCLUSION: Induction of NKG2D ligands by VPA increased the susceptibility of cancer cells that are recognised by NKG2D to cytolysis by gammadelta T-cells. Valproic Acid 42-45 killer cell lectin like receptor K1 Homo sapiens 25-30 21115900-7 2010 CONCLUSION: Induction of NKG2D ligands by VPA increased the susceptibility of cancer cells that are recognised by NKG2D to cytolysis by gammadelta T-cells. Valproic Acid 42-45 killer cell lectin like receptor K1 Homo sapiens 114-119 20028385-0 2010 Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Valproic Acid 95-108 killer cell lectin like receptor K1 Homo sapiens 24-29 20028385-1 2010 Valproic acid (VPA), a histone deacetylase inhibitor, upregulates NKG2D ligands (NKG2DLs) on some monocytic and lymphoid leukemic cells. Valproic Acid 0-13 killer cell lectin like receptor K1 Homo sapiens 66-71 20028385-1 2010 Valproic acid (VPA), a histone deacetylase inhibitor, upregulates NKG2D ligands (NKG2DLs) on some monocytic and lymphoid leukemic cells. Valproic Acid 15-18 killer cell lectin like receptor K1 Homo sapiens 66-71 17993609-0 2008 NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Valproic Acid 71-84 killer cell lectin like receptor K1 Homo sapiens 0-5 17993609-8 2008 Accordingly, induction of cell-surface NKG2D-L by treatment with the histone deacetylase inhibitor, valproic acid, rendered cells more sensitive to NK cytolysis. Valproic Acid 100-113 killer cell lectin like receptor K1 Homo sapiens 39-44 16024634-0 2005 Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Valproic Acid 130-146 killer cell lectin like receptor K1 Homo sapiens 79-84 16024634-5 2005 By microarray studies, we found evidence that treatment of human hepatocellular carcinoma cells with the histone deacetylase inhibitor (HDAC-I) sodium valproate (VPA) mediates recognition of cancer cells by cytotoxic lymphocytes via NKG2D. Valproic Acid 144-160 killer cell lectin like receptor K1 Homo sapiens 233-238 16024634-5 2005 By microarray studies, we found evidence that treatment of human hepatocellular carcinoma cells with the histone deacetylase inhibitor (HDAC-I) sodium valproate (VPA) mediates recognition of cancer cells by cytotoxic lymphocytes via NKG2D. Valproic Acid 162-165 killer cell lectin like receptor K1 Homo sapiens 233-238 19151770-0 2009 Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Valproic Acid 103-119 killer cell lectin like receptor K1 Homo sapiens 31-36 19151770-3 2009 Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells. Valproic Acid 115-131 killer cell lectin like receptor K1 Homo sapiens 275-280 19151770-3 2009 Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells. Valproic Acid 133-136 killer cell lectin like receptor K1 Homo sapiens 275-280